Tianjing Biotechnology grants Sanofi the rights to Yulelimab in China with a down payment of 250 million yuan
cjczf
发表于 昨天 20:15
3727
0
0
Beijing News Tianjing Biotech announced on its official WeChat official account on September 25 that it had reached strategic cooperation with Sanofi on the development, production and commercialization of the globally innovative CD73 antibody uliledlimab independently developed by Tianjing Biotech in Greater China.
Yulelimumab is an innovative CD73 antibody with differentiated advantages, which enhances the body's immune response to cancer cells by regulating the tumor microenvironment. At present, the drug is undergoing critical research in China in combination with trastuzumab for the treatment of advanced non-small cell lung cancer (NSCLC). At the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), Tianjing Biotechnology released data from phase 1b/2 clinical studies conducted in the United States and China. Data shows that 31% of newly diagnosed NSCLC patients have a therapeutic response to combination therapy; Among patients with high CD73 expression and PD-L1 positivity, 63% of patients responded to combination therapy. The biomarker analysis results showed that high expression of tumor CD73 is closely related to treatment response, further suggesting the potential of CD73 expression as a predictive biomarker.
According to the terms of the agreement, Sanofi will be granted the exclusive license to develop, produce and commercialize Urinary McAb in Chinese Mainland, Hong Kong, Macao and Taiwan. Tianjing Biotechnology will receive a down payment and a series of milestone payments, including two recent milestone payments. Tianjing Biotechnology will lead the clinical development of Yulelimumab for specific cancer indications, and be responsible for clinical drug supply and long-term commercial production. Sanofi will jointly bear part of the clinical development costs and lead the commercialization of the product in Greater China.
Sanofi will make a down payment of approximately 32 million euros (approximately 250 million yuan) and recent milestone payments, as well as specific registration and sales milestone payments, to Tianjing Biotechnology; The maximum potential total consideration shall not exceed 213 million euros (approximately 1.7 billion yuan). After the commercialization of the product, Tianjing Biotechnology will have the right to receive a tiered royalty based on the net sales of Yulelimab in Greater China, up to a double-digit percentage. In addition to the financial terms mentioned above, Tianjing Biotechnology will also receive additional milestone payments upon regulatory approval for each new indication of Yulelimab.
TJ Biopharma is a biotechnology company focused on innovative therapies for autoimmune diseases and tumors, committed to bringing breakthrough treatment methods to patients worldwide through cutting-edge innovation.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Stock god Buffett's latest move exposed: cashed out 6.3 billion yuan! Why does he frequently sell Bank of America?
- Beike Enters Real Estate Development: Its subsidiary Beihaojia acquires land in Chengdu for over 1 billion yuan and plans to independently operate high-end residential projects
- Suddenly! Buffett's deputy sold off heavily, nearly 1 billion yuan
- Former Chinese billionaire Zhao Changpeng confirms that he is about to be released from prison! Previously sentenced to 4 months in prison with a net worth of over 230 billion yuan
- JD Xiaoku has accumulated over 10 billion yuan in revenue for users
- Beihao Home will acquire land in Chengdu for nearly 1.1 billion yuan and independently operate high-end residential projects. Beike: not a developer
- Douyu's Q2 revenue was 1.032 billion yuan
- Douyu: Total revenue of 1.032 billion yuan in Q2 2024
- In the first half of 2024, Huize achieved a total revenue of 590 million yuan
- Stock god Buffett sells Bank of America stocks again, cashing out nearly 9 billion yuan in total
-
大雪と網易が「複合」した後、大雪系傘下のゲームが次々と国服に復帰しつつあり、9月25日、魔獣世界に続き、大雪系ゲームの「現金牛」、カードゲーム「炉石伝説」が正式に国服に復帰した。午前7時26分、新京報貝殻 ...
- vvsky
- 前天 17:14
- 支持
- 反对
- 回复
- 收藏
-
上証報中国証券網(何奎記者)は9月25日、国内頭部保険電子商取引サービスプラットフォームの慧択氏が米国株の開場前に発表した2024年第2四半期の未監査業績報告によると、上半期の慧択全プラットフォームによる総 ...
- 18010063851
- 昨天 11:44
- 支持
- 反对
- 回复
- 收藏
-
百勝中国9月23日のニュースによると、百勝中国と保利発展ホールディングスはこのほど、広州保利発展広場で戦略協力協定に調印した。双方はそれぞれのビジネス分野での技術、管理、ブランドの優位性を十分に利用し、 ...
- 寒郁轩良
- 前天 16:28
- 支持
- 反对
- 回复
- 收藏
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...
- 虚空一粒沙2017
- 昨天 21:42
- 支持
- 反对
- 回复
- 收藏